Don’t miss these opportunities to advance your research with free NIH collaborative programs that will support your work to develop innovative cancer technologies.
The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center is committed to informing small businesses about federal programs that are pivotal to advancing the development of technologies to support the prevention, research, diagnosis, and treatment of cancer. We encourage you to review the opportunities below and consider applying.
Additionally, please see below for a special announcement regarding the NCI Clinical Assay Development Program (CADP).
NCI NExT Program
The NCI Experimental Therapeutics (NExT) Program provides researchers with access to NCI’s anticancer drug discovery and development resources. These resources help advance projects from initial discovery to proof-of-concept clinical trials, to ultimately benefit people living with cancer. Take advantage of this opportunity to be mentored by experts at NCI. Any intellectual property brought to the program will stay with the applicant and licensing rights may be given on certain inventions.
The NExT Program accepts applications focused on cancer therapeutic interventions including but not limited to the development of medical devices and imaging agents. Special consideration is given to applications that address unmet needs in oncology, including approaches to orphan malignancies and pediatric cancers.
The next deadline to apply is February 15, 2014. Learn more about the NCI Division of Cancer Treatment and Diagnosis.
For questions about the NExT Program, please contact Barbara Mroczkowski at NCINExTinfo@mail.nih.gov.
NCI PREVENT Program
The NCI PREVENT Cancer Preclinical Drug Development Program provides resources to advance novel cancer-preventive chemical or biological agents and biomarkers to clinical testing. This partnership with NCI will enable the progression of promising cancer preventive chemical or biological agents (singly or in combination) and biomarkers from the lab to proof-of-concept clinical testing and registration or validation.
The PREVENT Program is a flexible entry-point system that will optimize and test an agent depending on the stage of development, with the goal of filing an Investigational New Drug Application with the U.S. FDA and entering the agent into clinical testing.
The next deadline to apply is March 3, 2014. Learn more about the NCI Division of Cancer Prevention.
For questions about the PREVENT Program, please email NCIPREVENT@mail.nih.gov.
Please visit http://sbir.cancer.gov/ to learn more about the NCI SBIR & STTR Programs
The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.